Centessa Pharmaceuticals: Buy Rating Based on Promising Orexin Agonist Program and Market Potential

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Centessa Pharmaceuticals and keeping the price target at $35.00.

Kostas Biliouris has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ promising developments and market potential. The analyst highlights the company’s diversified pipeline, particularly focusing on their orexin agonist program, which includes the promising candidate ORX750. This candidate has shown strong safety and efficacy data, positioning it as potentially best-in-class within its category.
Furthermore, the analyst notes the significant commercial opportunities within the orexin class, driven by anticipated improvements in diagnosis rates and treatment adherence. With expectations of substantial market growth and the potential for multiple assets to thrive, Centessa Pharmaceuticals is well-positioned to capitalize on these opportunities. The analyst’s confidence is further bolstered by the company’s strategic efforts to expand beyond narcolepsy, tapping into a broader market potential.

In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $39.00 price target.